DSGN: Design Therapeutics raises ATM capacity to $200M from $100M
Design raises up to $200M more via Jefferies at-the-market program; $66.3M already sold, stock at $10.34 on Nov 3, 2026.
What this filing says
Design Therapeutics has expanded its at-the-market share sale program with Jefferies, raising the total it may sell from $100 million to $200 million. About $66.3 million has already been sold under the program, so the new capacity is in addition to that amount. For a shareholder, this means the company can issue more new shares over time, which may dilute existing holders' stake.
Key figures
- Total program capacity
- $200,000,000
- Prior program capacity
- $100,000,000
- Amount sold to date
- $66,330,496.30
- Last reported share price
- $10.34
Positive for shareholders
- The company has expanded its available funding capacity, which may help it fund operations without a separate offering.
Negative for shareholders
- Additional share sales under the program could dilute the ownership of existing shareholders.
- Investing in the company's securities involves a high degree of risk, according to the filing.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- At-the-market (ATM) offering:
- A way for a company to sell new shares gradually into the open market through a broker rather than in one large offering.
- Prospectus supplement:
- A document that updates or adds information to an earlier prospectus covering a securities offering.
- Form S-3:
- A short-form registration statement the SEC allows certain companies to use to register securities for sale.
FAQ
How much can Design Therapeutics sell under its share sale program now?
The filing states the company may offer and sell up to $200,000,000 of common stock, inclusive of the $66,330,496.30 already sold under the program.
Who is acting as agent for Design Therapeutics' share sales?
Jefferies LLC is acting as agent under the Open Market Sale Agreement dated April 27, 2022.
Historical context for DSGN
Across the 17 sessions after earlier DSGN headlines, the stock closed higher 11 times and lower 6 times, with a median move of 4.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DSGN | SPY |
|---|---|---|---|
| Nov 5, 2026 | Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates | -9.0% | -4.4% |
| Oct 2, 2026 | Wells Fargo initiated coverage on Design Therapeutics with a new price target | +0.8% | +0.7% |
| Sep 2, 2026 | Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference | +2.6% | +0.4% |
| Aug 3, 2026 | Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results | +4.8% | +1.4% |
| Jun 30, 2026 | Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 | +1.6% | +0.8% |
| May 28, 2026 | Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference | -3.2% | +0.6% |
Keep researching DSGN
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow DSGN and get a push notification the moment its next story breaks.